ClinicalTrials.gg

Thrombocytopenia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 484 studies for Thrombocytopenia across more than 10 countries. 102 are recruiting or about to start. 252 of them are mainly about Thrombocytopenia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its 6 narrower conditions too, such as Purpura, Thrombocytopenic, Idiopathic: 1,095 studies, 298 open.

Status

Completed
233
Recruiting
66
Status unknown
60
Terminated
58
Not yet recruiting
32
Withdrawn
19

Phase

Phase 2
180
Phase 3
85
Phase 1
55
Phase 4
32
Early Phase 1
8

Where

United States
177
China
108
France
58
Italy
39
Canada
34
Germany
33

Who develops what

Add Thrombocytopenia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 3 with this as their studies’ main aim; 3 with a live phase 3 study; 0 primary completions in the next 12 months. Compare Chongqing Peg-Bio Biopharm, Jiangsu HengRui Medicine and Takeda here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ruxolitinibRecent, limited
Evidence
  • NCT05980806 · Karyopharm Therapeutics Inc · Phase 2 · live · background · “Ruxolitinib” · registered Jul 2023
  • NCT05037760 · Takeda · Phase 2 · live · background · “Ruxolitinib” · registered Aug 2021
Incyte Corporation72% of its industry studiesUS: Incyte Corporation (FDA 2011)EU: Novartis (EMA 2012) + 1 other11 study
pacritinibRecent, limited
Evidence
  • NCT05980806 · Karyopharm Therapeutics Inc · Phase 2 · live · background · “Pacritinib” · registered Jul 2023
Swedish Orphan Biovitrum67% of its industry studiesUS: Swedish Orphan Biovitrum (FDA 2022)11 study
momelotinibRecent, limited
Evidence
  • NCT05980806 · Karyopharm Therapeutics Inc · Phase 2 · live · background · “Momelotinib” · registered Jul 2023
GlaxoSmithKline100% of its industry studiesUS: GlaxoSmithKline (FDA 2023)EU: GlaxoSmithKline (EMA 2024)11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Thrombocytopenia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Antimetabolites 1 open · Calcineurin inhibitors 1 open · Antifibrinolytics 1 open · Corticosteroids 1 open

Coming up

26studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger. 10 (15%) take children under 18. 1 (2%) are for women only and 0 (0%) for men only; 3 (5%) take healthy volunteers.

Recruiting studies that take each age, of 66
AgeWomenMen
105 (8%)5 (8%)
1863 (95%)62 (94%)
3062 (94%)61 (92%)
4062 (94%)61 (92%)
5062 (94%)61 (92%)
6559 (89%)58 (88%)
7554 (82%)53 (80%)
8548 (73%)47 (71%)

Across all 484 studies, recruiting or not: 28% stop at 75 or younger and 15% at 65; 23% take children; 4% are for women only and 1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Thrombocytopenia studies take

Of 54 phase 2 interventional studies under Thrombocytopenia, half reached primary completion within 36 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 115 mo6–36 · 18 studies——
Phase 236 mo28–81 · 54 studies—63 mo33–83 · 44 studies
Phase 334 mo22–45 · 29 studies——
Interventional, no phase20 mo11–44 · 25 studies——
Observational32 mo20–56 · 41 studies—27 mo13–63 · 36 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 484. Browse all 484 → or search them.